Loading
Epigenetics and DNA Methylation / Ferroptosis and Cancer Prognosis · Journal article
Discover Oncology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a comprehensive narrative review that maps deubiquitinase regulatory networks implicated in breast cancer malignancy, therapy resistance, and immune evasion through synthesis of preclinical mechanistic studies and observational correlations. While it identifies DUBs as potential prognostic biomarkers and therapeutic targets, the authors acknowledge that prospective clinical validation and pharmacological development remain incomplete, with no DUB inhibitors yet in clinical trials for breast cancer.
Narrative literature review. Breast cancer malignancy; ERα-positive and triple-negative breast cancer subtypes.
USP36, USP22, USP15, and USP1 stabilize wild-type and mutant ERα to enable acquired endocrine resistance in ERα-positive disease USP14-CDK1, USP20-SNAI2, USP28-Snail1, and USP41-Snail axes promote cell cycle progression and metastasis OTUB1-MYC, USP11-PGAM5, USP24-DHODH, and USP5-GPX4 mediate metabolic and ferroptosis defense mechanisms in triple-negative breast cancer
Pharmacological inhibitors against USP7, USP24, UCHL1, and FASN show preclinical efficacy but none has entered clinical trials for breast cancer
Clinicians should recognize that DUBs are emerging as mechanistic drivers of breast cancer progression and resistance, but implementation remains at the research stage pending clinical validation of biomarkers and development of selective, well-tolerated inhibitors.
This is a comprehensive narrative review synthesizing mechanistic and preclinical findings on deubiquitinases in breast cancer, with no clinical trial data, prospective validation, or regulatory approval to support practice change.
As stated by the source record.
Clinicians should recognize that DUBs are emerging as mechanistic drivers of breast cancer progression and resistance, but implementation remains at the research stage pending clinical validation of biomarkers and development of selective, well-tolerated inhibitors.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose Breast cancer progression is orchestrated by a networked regulatory architecture of deubiquitinases (DUBs), defined by functional convergence, pathway pleiotropy, and complementary parallel layers. This review elucidates how this integrated circuitry governs breast cancer malignancy, therapy resistance, and immune evasion, and evaluates its clinical translational potential. Methods We comprehensively reviewed recent literature on DUBs in breast cancer, synthesizing findings on molecular mechanisms, substrate specificity, pathway crosstalk, and clinical correlations across breast cancer subtypes. Results DUBs stabilize transcription factors (FOXM1, SNAI2), epigenetic modifiers (LSD1), and signaling nodes (ERα, HER2, MYC) to drive proliferation and stemness maintenance. In ERα-positive disease, convergent DUBs including USP36, USP22, USP15, and USP1 amplify ligand-dependent signaling and enable acquired endocrine resistance through stabilization of both wild-type and mutant ERα. DUBs accelerate cell cycle via USP14-CDK1 and promote metastasis through parallel USP20-SNAI2, USP28-Snail1, and USP41-Snail axes. Metabolically, OTUB1-MYC drives aerobic glycolysis, while USP11-PGAM5, USP24-DHODH, and USP5-GPX4 constitute complementary non-redundant ferroptosis defense layers particularly active in triple-negative breast cancer. DUBs also mediate DNA repair fidelity (USP4-BRCA1) and multidrug resistance (USP7-ABCB1). Beyond cell-intrinsic functions, DUBs modulate the tumor immune microenvironment, with the DUBRI signature stratifying immunotherapy response and the FASN-USP5-GPX4 axis linking ferroptosis sensitization to immune re-activation. Clinically, aberrant DUB expression correlates with aggressive features and poor prognosis; DUB-based signatures and serum exosomal UCHL1 show promise as candidate biomarkers, though prospective validation is lacking. Pharmacological targeting of DUBs—using inhibitors against USP7, USP24, UCHL1, or FASN—demonstrates preclinical efficacy in experimental models, but none has yet entered clinical trials for breast cancer. Conclusion DUBs function as central signaling hubs orchestrating malignant progression, treatment resistance, and immune evasion in breast cancer, positioning them as promising prognostic biomarkers and therapeutic targets. Addressing challenges in isoform selectivity, context-dependent functions, and substrate specificity will be essential to realize their clinical potential.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.